Pacritinib - CAS# 937272-79-2 adib) 37)38/h1-9

37)38/h1-9

CAS Number: 1010085-13-8

Chemical Name: 3-[3-({[(7S)-3

BxPC-3 primary tumor growth in the MIA-PaCa-2 early-stage model and early-stage model of BxPC-3

Pharmacological brake-release of mRNA translation enhances cognitive memory

Pacritinib - CAS# 937272-79-2 adib) 37)38/h1-9Pacritinib, also known as SB1518, is a n orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Pacritinib competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK STAT signaling pathway, and so caspase dependent apoptosis. JAK2 is the most common mutated gene in bcr abl negative myeloproliferative disorders; the JAK2V617F gain of